AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33252337
Drug: CT-guided injection
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided injection with botulinum toxin
Trial: 33252337
Drug: CT-guided injection
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided injection without botulinum toxin (Control)
Trial: 35138714
Drug: Psilocybin in
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin in combination with psychotherapy
Trial: 35138714
Drug: Escitalopram in
RxNorm normalized name: Product containing escitalopram in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram in combination with psychotherapy
Trial: 35483093
Drug: Adaptive COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive COVID-19 Treatment Trial
Trial: 32069516
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (fasting condition)
Trial: 32069516
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (high-calorie, high-fat meal 1 hour postdose)
Trial: 32069516
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (high-calorie, high-fat meal 2 hours postdose)
Trial: 36228485
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day pyridoxine
Trial: 33296464
Drug: Probiotics (Lactiplantibacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2) - total daily dose of 109 CFU for 12 weeks
Trial: 32606658
Drug: Commercial etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial etoricoxib tablets
Trial: 33280934
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality sessions for 15 min twice a week for 6 weeks
Trial: 32505378
Drug: Dexmedetomidine [1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine [1.0 μg.kg‐1 body weight] and morphine [0.48 mg.kg‐1 body weight] (COM Group)
Trial: 32505378
Drug: Morphine [0.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine [0.48 mg.kg‐1] (MOR Group)
Trial: 32505378
Drug: Dexmedetomidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine and morphine (COM Group)
Trial: 32505378
Drug: Morphine (MOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (MOR Group)
Trial: 33756250
Drug: BDC supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDC supplementation (150 mg/kg)
Trial: 32620917
Drug: dMMR CRCs
RxNorm normalized name: PILOCARPINE 11MG/UNT OPH,CRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dMMR CRCs bearing receptor tyrosine kinase fusion
Trial: 36332823
Drug: Analog insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analog insulin
Trial: 36174744
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous hydroxocobalamin (IV-HOC), 5-gram dose
Trial: 35175317
Drug: Sacubitril/valsartan (194/206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (194/206 mg)
Trial: 32657457
Drug: Glycopyrrolate up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate up to 4.5 mg/d
Trial: 35708706
Drug: Port Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Port Delivery System (PDS) with ranibizumab, 100 mg/mL, fixed refill exchanges every 24 weeks
Trial: 35708706
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injections, 0.5 mg, every 4 weeks
Trial: 35708706
Drug: Concurrent fellow-eye
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent fellow-eye injections
Trial: 35734974
Drug: Hydrogen/oxygen inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen/oxygen inhalation for 13 weeks
Trial: 35734974
Drug: Hydrogen/oxygen inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen/oxygen inhalation
Trial: 35734974
Drug: Hydrogen treatment
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen treatment
Trial: 34081385
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose to induce PBH
Trial: 35437929
Drug: Sacubitril/valsartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (200 mg/day)
Trial: 32910197
Drug: Collagen/cell group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen/cell group (hUC-MSC-laden collagen hydrogel intramyocardial injection)
Trial: 33527576
Drug: L-menthol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol (160 mg) and Placebo
Trial: 35561721
Drug: Human intramuscular
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human intramuscular antitoxin
Trial: 35561721
Drug: Equine intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine intramuscular antitoxin
Trial: 33358790
Drug: High rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High rate of milk replacer (HMR treatments); n = 12 calves
Trial: 36083793
Drug: Allogeneic cardiosphere-derived
RxNorm normalized name: Allogeneic Cardiosphere-Derived Cells
DrugBank: Allogeneic Cardiosphere-Derived Cells (DB15744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic cardiosphere-derived cell (CDC) therapy (20 × 10^6 CDCs)
Trial: 36083793
Drug: Allogeneic cardiosphere-derived
RxNorm normalized name: Allogeneic Cardiosphere-Derived Cells
DrugBank: Allogeneic Cardiosphere-Derived Cells (DB15744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic cardiosphere-derived cell (CDC) therapy with cyclosporine (2.5 mg/kg iv and 100 mg/day po)
Trial: 33781617
Drug: Community health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community health worker-led multicomponent intervention (health education, monthly telephone follow-ups, navigation assistance)
Trial: 35779560
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily if <100 kg, 40 mg twice daily if ≥100 kg) for 21 days
Trial: 33121228
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) infusion (8 µg/min)
Trial: 33121228
Drug: Phenylephrine (PE)
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine (PE) infusion (100 µg/min)
Trial: 32620262
Drug: High-dose TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TXA (50 mg kg−1 followed by 5 mg kg−1 h−1)
Trial: 32620262
Drug: Low-dose TXA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose TXA (10 mg kg−1 followed by 5 mg kg−1 h−1)
Trial: 36494329
Drug: SOM3355 (bevantolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOM3355 (bevantolol hydrochloride) 200 mg twice daily
Trial: 32199156
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of 0.45 g/kg
Trial: 32358349
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional therapy
Trial: 34989759
Drug: Flower essence
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flower essence therapy (4 drops, 4 times a day for 60 days)
Trial: 34849651
Drug: Standard ATT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ATT plus daily 1000 mg metformin (METRIF)
Trial: 32979939
Drug: High-dose varenicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose varenicline (1 mg twice daily; 0.5 mg twice daily if bodyweight ≤55 kg)
Trial: 32979939
Drug: Low-dose varenicline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose varenicline (0.5 mg twice daily; 0.5 mg once daily if bodyweight ≤55 kg)
Trial: 35017115
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of anal HSIL
Trial: 32763541
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus enhanced medication management (EMM)
Trial: 32763541
Drug: PE plus
RxNorm normalized name: Acetaminophen/Phenylephrine Hydrochloride 500 MG-5 MG Oral Tablet [ORANYL PE PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE plus sertraline hydrochloride
Trial: 34190422
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) at doses of 600 or 1000 mg per day for 12 weeks
Trial: 34964262
Drug: Metformin during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin during pregnancy
Trial: 34964262
Drug: Post partum
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post partum metformin concentration
Trial: 34060169
Drug: Health literacy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health literacy education (four weekly training sessions)
Trial: 34508365
Drug: Treatment reminders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment reminders (outpatient appointment reminders a day before appointment and medication reminders on a weekly basis)
Trial: 34508365
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without reminders
Trial: 33929052
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiST) applied once weekly for 6 weeks
Trial: 33929052
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiST) applied twice weekly for 3 weeks
Trial: 33929052
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between once weekly and twice weekly LiST
Trial: 35300814
Drug: Pelacarsen (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelacarsen (20-80 mg cumulative monthly doses)
Trial: 34066319
Drug: Eight-session multicomponent
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight-session multicomponent intervention program based on group psychological therapy and adventure activities
Trial: 35175414
Drug: Intravenous scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous scopolamine before stapling
Trial: 35230177
Drug: PartyWise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PartyWise intervention (telephone screening, brief counseling, web-based resources, and up to 8 weekly text messages)
Trial: 35705264
Drug: Bilateral posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral posterior quadratus lumborum block (QLB) with 20 mL of 0.375% ropivacaine on each side (150 mg total)
Trial: 35705264
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.4 mg morphine sulfate)
Trial: 35337143
Drug: Chisan®/ADAPT‐232 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chisan®/ADAPT‐232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks
Trial: 35337143
Drug: Chisan® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chisan® treatment
Trial: 35181380
Drug: Recommendation agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendation agents
Trial: 32441643
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) administered subcutaneously at 162 mg every 1 or 2 weeks in the GiACTA trial.
Trial: 32441643
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) administered via standard IV dose (8 mg/kg/month) or subcutaneously (162 mg/week) in clinical practice.
Trial: 35956412
Drug: Study formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study formulation (A)
Trial: 35956412
Drug: Study formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study formulation + eye lubricant (A + L)
Trial: 35956412
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + eye lubricant (P + L)
Trial: 35866833
Drug: nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel plus gemcitabine (first-line chemotherapy)
Trial: 33639007
Drug: Proximal nontouch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal nontouch biofield therapy
Trial: 35565731
Drug: Resveratrol 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 75 mg twice daily for three months
Trial: 33379851
Drug: Single Negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Negative Pressure Therapy (SNPT)
Trial: 33379851
Drug: Cyclic Alternating
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic Alternating Negative Pressure Therapy (CANPT)
Trial: 33138628
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus 100 mg aspirin daily
Trial: 35585282
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg for 24 weeks
Trial: 35596117
Drug: ACT-1014-6470 (0.5-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-1014-6470 (0.5-200 mg)
Trial: 35596117
Drug: ACT-1014-6470 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-1014-6470 (10 mg) under fasted conditions
Trial: 33151286
Drug: Indoximod plus
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoximod plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Trial: 33151286
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Trial: 33444206
Drug: Personalised dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalised dietary advice and protein-enriched food products to increase protein intake to at least 1.2 g/kg adjusted BW/day
Trial: 33444206
Drug: Personalised dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalised dietary advice and protein-enriched food products plus advice to consume 7.5-10 g protein through protein-enriched foods within half an hour after usual physical activity
Trial: 33354268
Drug: At-home local
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home local vibration therapy (LVT) with NOVAFON Pro Sk2/2: 50/100 Hz, applied bilaterally for 16 minutes daily for 1 week
Trial: 35400584
Drug: Emibetuzumab plus
RxNorm normalized name: Emibetuzumab
DrugBank: Emibetuzumab (DB11849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emibetuzumab plus Erlotinib (750 mg every 2 weeks + 150 mg once daily)
Trial: 35400584
Drug: Emibetuzumab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emibetuzumab monotherapy (750 mg every 2 weeks)
Trial: 35400584
Drug: Emibetuzumab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emibetuzumab monotherapy
Trial: 34825590
Drug: Buddy-style intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buddy-style intervention (5-10 min weekly)
Trial: 35738778
Drug: Single-dose ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ivermectin (12 mg)
Trial: 35738778
Drug: Double-dose ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-dose ivermectin (24 mg)
Trial: 32052907
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of combination formulation of vitamin C, vitamin E, and ferulic acid after Q-switched Nd:YAG laser treatment
Trial: 35791276
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) upgrade
Trial: 34610611
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injected and patient‐controlled analgesic pump used (Control)
Trial: 32240186
Drug: Peer mentoring
RxNorm normalized name: IRRIGATOR,GREER MENTOR #6004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer mentoring program with monthly one-on-one and group sessions
Trial: 34427475
Drug: Mechanical thrombectomy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical thrombectomy with the detachable Solitaire thrombectomy device and best medical therapy (BMT)
Trial: 35614161
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic chemotherapy (OMC) with celecoxib 200 mg twice daily and methotrexate 15 mg/m2 weekly for 12 months
Trial: 35614161
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic chemotherapy (OMC)
Trial: 34446053
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course radiotherapy (25 Gray in 5 fractions over one week) with concomitant durvalumab (1500 mg every 4 weeks), followed by FOLFOX (85 mg/m2 oxaliplatin, 350 mg folinic acid, and 400 mg/m2 bolus 5-FU on day 1, followed by 2400 mg/m2 5-FU infusion over 46-48 hours, every 2 weeks) and durvalumab.
Trial: 34446053
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course chemoradiotherapy (50 Gray to primary tumour in 25 fractions over 5 weeks with concomitant oral capecitabine 825 mg/m2 twice per day on days of radiotherapy) with durvalumab followed by FOLFOX and durvalumab.
Trial: 36196729
Drug: Liraglutide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3 mg) + Metformin (2x1,000 mg)
Trial: 36196729
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (2x1,000 mg)
Trial: 32179067
Drug: Psychoeducation‐based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation‐based cognitive rehabilitation intervention delivered in a group setting during 6 weekly 2.5‐hour classes.
Trial: 36403975
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca block (FIB) with 30 mL of 0.185% ropivacaine
Trial: 32556602
Drug: Adavosertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (300 mg) in fed state (high-fat, high-calorie meal)
Trial: 32556602
Drug: Adavosertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (300 mg) in fasted state
Trial: 34446531
Drug: rhTNK‐tPA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNK‐tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Trial: 34446531
Drug: rt‐PA 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA 0.9 mg/kg (10% bolus + 90% infusion/1 hour) to a maximum of 90 mg
Trial: 32155622
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate (POC)
Trial: 36131360
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of SHR4640 and febuxostat
Trial: 32513359
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing Polymyxin B and Bacitracin (Group A, n=28)
Trial: 35762293
Drug: Mexiletine (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (333 mg)
Trial: 35762293
Drug: Lacosamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (300 mg)
Trial: 33545096
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge
Trial: 32423239
Drug: SHP465 MAS
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 MAS (12.5-75 mg)